Virus engineered to fight cancer shows promise in early trial
NCT ID NCT04695327
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety and find the right dose, not to measure how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TILT-123 (a modified virus that infects and kills cancer cells while releasing immune-boosting proteins)
What this could lead to
If successful, this could point toward a new way to treat advanced solid tumors by using a virus to attack cancer and stimulate the immune system.
What could go wrong
This is an early, small Phase 1 trial focused on safety, not effectiveness. The virus may not work in all patients or could cause side effects like flu-like symptoms or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Docrates Cancer Center
Helsinki, Uusima, 00180, Finland
-
Helsinki University Hospital
Helsinki, Uusima, 00029, Finland